Seelos Therapeutics EBITDA 2010-2022 | SEEL

Seelos Therapeutics ebitda from 2010 to 2022. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Seelos Therapeutics Annual EBITDA
(Millions of US $)
2021 $-60
2020 $-19
2019 $-30
2018 $-3
2017 $-11
2016 $-14
2015 $-21
2014 $-22
2013 $-17
2012 $-17
2011 $-18
2010 $-10
2009 $26
Seelos Therapeutics Quarterly EBITDA
(Millions of US $)
2022-03-31 $-14
2021-12-31 $-27
2021-09-30 $-11
2021-06-30 $-6
2021-03-31 $-16
2020-12-31 $-6
2020-09-30 $-4
2020-06-30 $-3
2020-03-31 $-6
2019-12-31 $-10
2019-09-30 $-4
2019-06-30 $-3
2019-03-31 $-12
2018-12-31 $-1
2018-09-30 $-1
2018-06-30 $-0
2018-03-31 $-1
2017-12-31 $-3
2017-09-30 $-4
2017-06-30 $-2
2017-03-31 $-2
2016-12-31 $-3
2016-09-30 $-2
2016-06-30 $-5
2016-03-31 $-5
2015-12-31 $-3
2015-09-30 $-6
2015-06-30 $-6
2015-03-31 $-6
2014-12-31 $-17
2014-09-30 $-3
2014-06-30 $1
2014-03-31 $-4
2013-12-31 $-4
2013-09-30 $-3
2013-06-30 $-4
2013-03-31 $-6
2012-12-31 $-7
2012-09-30 $-2
2012-06-30 $-4
2012-03-31 $-4
2011-12-31 $-4
2011-09-30 $-2
2011-06-30 $-8
2011-03-31 $-3
2010-12-31 $-18
2010-09-30 $1
2010-06-30 $-2
2010-03-31 $-2
2009-12-31 $27
2009-09-30 $-1
2009-06-30 $-1
2009-03-31 $1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.072B $0.000B
Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which are in clinical stage. Seelos Therapeutics Inc., formerly known as Apricus Biosciences Inc., is based in New York, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.938B 9.97
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.718B 16.92
Biohaven Pharmaceutical Holding (BHVN) United States $10.276B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.817B 46.07
Emergent Biosolutions (EBS) United States $1.560B 6.68
Myovant Sciences (MYOV) United Kingdom $1.185B 0.00
Zymeworks (ZYME) Canada $0.306B 0.00
Gelesis Holdings (GLS) United States $0.112B 0.00
Ambrx Biopharma (AMAM) United States $0.102B 0.00
Enzo Biochem (ENZ) United States $0.101B 0.00
SQZ Biotechnologies (SQZ) United States $0.090B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00